Sponsor:
Viridian Therapeutics, Inc.
Code:
NCT07832136
Conditions
Thyroid Eye Disease
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Interventions
veligrotrug (LUMVOA™)
Brief summary:
Conditions
Thyroid Eye Disease
Study ID
NCT07832136
Start date
Oct 19, 2026
Status verified date
Nov, 2026
Completion date
Sep, 2027
Anticipated
Primary completion date
Apr, 2027
Anticipated
Eligibility Criteria
Sex: All
Age: 18 - 70+
Healthy Volunteers: Not accepted
Enrollment
30 participants
Anticipated
Intervention Model
Single group
Primary purpose
Treatment
Arms
experimental: 5 IV infusions of 10 mg/kg of veligrotug
Interventions
veligrotrug (LUMVOA™)
Primary outcome measure
Central contacts
Locations
Office of Dr. Amy Patel Jain, MD
Recruiting
Newport Beach, California, United States, 92660
Contacts
Sarasota Retina Institute
Recruiting
Sarasota, Florida, United States, 34239
Contacts
Ophthalmic Consultants of Boston
Recruiting
East Weymouth, Massachusetts, United States, 02189
Contacts
The Center for Eye and Facial Plastic Surgery
Recruiting
Somerset, New Jersey, United States, 08873
Contacts
Neuro-Eye Clinical Trials
Recruiting
Houston, Texas, United States, 34239
Contacts
Sponsor
Viridian Therapeutics, Inc.
Last update posted
Nov 20, 2026
Last verified
Nov, 2026
Keywords
Trial information was received from ClinicalTrials.gov and was last updated on 2026-11-21. This information was provided to ClinicalTrials.gov by Viridian Therapeutics, Inc. on 2026-11-20. Recruitment status is synced daily from ClinicalTrials.gov and may not reflect the sponsor's current status. Confirm during your call.